undamentalytics Newsletter
Sign in

Newgenivf Group Ltd (NIVF) stock

Add to watchlist

Add holding +

NASDAQ: NIVF Nasdaq Health Care Facilities

B Fundamentals grade

Newgenivf Group Ltd is a US-listed company in the health care facilities industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Newgenivf Group Ltd is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: share count (0m) is 0.025x the market-data count (10m). We'll show the comparison once resolved.

Newgenivf Group Ltd valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling8 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds1 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Newgenivf Group files

Where Newgenivf stands after its latest Filing

Revenue for the twelve months was $24m, up 336.3% on a year earlier, faster than the 5.8% growth a quarter earlier. That growth ranks 1 of 13 among the health care facilities companies we cover. Free-cash-flow margin fell to -46.7% from 34.4% a year earlier. Operating margin narrowed to -45.2% from 4.8%. The diluted share count is up 2731009.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 3 of our 6 financial-health checks.

Our model value for Newgenivf Group is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Newgenivf Group Ltd's trailing-twelve-month revenue grew 336.3% year on year, with a free-cash-flow margin of -46.7%. Where it stands out: revenue growth of 336.3% ranks 1 of 13 health care facilities companies we cover. Where it lags: change in share count of 2731009.2% ranks 13 of 13 health care facilities companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 336.3% (+330.6pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 336.3% over the last 12 months, against a median of 14.0% for health care facilities companies we cover.
  • Growth speeding up. The growth rate is 330.6 points higher than a quarter earlier.

Things to watch

  • Loss-making. Operating margin is -45.2%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 23.9 points on a year ago.
  • Burning cash. Free cash flow was -46.7% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2731009.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 235% and a beta of 1.3 against the S&P 500.
  • Gross margin slipping. Gross margin is down 29.6 points on a year ago.

Price chart

  • 1 day-5.6%
  • 1 week-20.3%
  • 1 month-77.6%
  • This year-100.0%
  • 1 year-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$23.7M
Operating margin
-45.2%
Net margin
41.7%
EPS (TTM, diluted)
$3.04

Growth

Revenue growth
+336.3%
Change in growth rate
+330.6 pts
Share count change
+2731009.2%

Cash

Free cash flow (TTM)
-$11.1M
FCF margin
-46.7%
Stock pay % of revenue
-50.9%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Newgenivf Group Ltd valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (0m) is 0.025x the market-data count (10m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025
Share price$176256000.00$188352000.00$6998400.00$2384.64
Market value$5.08tn$1.9bn$833m$7.8bn
+ Net debt (− = net cash)−$27556−$54104$2m$4m
Enterprise value$5.08tn$1.9bn$835m$7.8bn
Multiples
Price / sales n/mn/m153.3xn/m
Price / earnings n/mn/m—n/m
Price / free cash flow n/m———
EV / EBITDA n/mn/m——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1365.12 +102% $65m +1277%
Next $2689.92 +97% $180m +177%

Next year's EPS estimate has moved −97.5% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −95.0% on 90 days ago. In the last 30 days, 0 analysts raised Newgenivf Group Ltd's forecast and 0 cut it.

Consensus EPS forecast Newgenivf Group Ltd, last 90 days
$0.00 $50000.00 $100000.00 $150000.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $27475.21 Current fiscal year, 60 days ago: $1365.12 Current fiscal year, 30 days ago: $1365.12 Current fiscal year, 7 days ago: $1365.12 Current fiscal year, Now: $1365.12 $1365.12 Next fiscal year, 90 days ago: $109728.03 Next fiscal year, 60 days ago: $2689.92 Next fiscal year, 30 days ago: $2689.92 Next fiscal year, 7 days ago: $2689.92 Next fiscal year, Now: $2689.92 $2689.92

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $27475.21$109728.03
60 days ago $1365.12$2689.92
30 days ago $1365.12$2689.92
7 days ago $1365.12$2689.92
Now $1365.12$2689.92

Positioning

Short interest
27.7%
of tradable shares
Days to cover
0.09
at average volume
Short interest, 1 month
+59745%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
3.2%
of shares
Employees
87
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
NIVF+7%−96%−100%−100%
Industry peers (median)+14%+17%+31%+13%
S&P 500+26%+25%+18%+11%
Months that ended higher
NIVF75%25%0%0%
S&P 50067%75%75%46%
Largest fall from a high during the year
NIVF−3%−98%−100%−100%
S&P 500−10%−8%−19%−9%

Worst fall since March 18, 2022: 100% from March 8, 2024 to November 2, 2026. Getting back needed a 23052454206% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.93 – $10955.52
From 52-week high
−100.0%
vs 50-day average
−94.7%
vs 200-day average
−99.8%
Volatility (1 year)
235%
Beta vs S&P 500
1.34

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Newgenivf Group Ltd in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Newgenivf Group Ltd
$0 $10M $20M $30M FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue (TTM), FY21 Q4: $4.1M Revenue (TTM), FY22 Q4: $5.9M Revenue (TTM), FY23 Q4: $5.1M Revenue (TTM), FY24 Q4: $5.4M Revenue (TTM), FY25 Q4: $23.7M $23.7M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY21 Q4 $4.1M
FY22 Q4 $5.9M
FY23 Q4 $5.1M
FY24 Q4 $5.4M
FY25 Q4 $23.7M
Revenue growth, TTM YoY Newgenivf Group Ltd
-100% 0% 100% 200% 300% 400% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY22 Q4: 44.3% Revenue growth, TTM YoY, FY23 Q4: -13.6% Revenue growth, TTM YoY, FY24 Q4: 5.8% Revenue growth, TTM YoY, FY25 Q4: 336.3% 336.3%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY22 Q4 44.3%
FY23 Q4 -13.6%
FY24 Q4 5.8%
FY25 Q4 336.3%
Operating margin (TTM) Newgenivf Group Ltd
-60% -40% -20% 0% 20% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Operating margin (TTM), FY21 Q4: 4.8% Operating margin (TTM), FY22 Q4: 6.7% Operating margin (TTM), FY23 Q4: 0.8% Operating margin (TTM), FY24 Q4: -21.4% Operating margin (TTM), FY25 Q4: -45.2% -45.2%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY21 Q4 4.8%
FY22 Q4 6.7%
FY23 Q4 0.8%
FY24 Q4 -21.4%
FY25 Q4 -45.2%
FCF margin (TTM) Newgenivf Group Ltd
-200% -150% -100% -50% 0% 50% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FCF margin (TTM), FY21 Q4: 34.4% FCF margin (TTM), FY22 Q4: 27.2% FCF margin (TTM), FY23 Q4: -35.7% FCF margin (TTM), FY24 Q4: -153.1% FCF margin (TTM), FY25 Q4: -46.7% -46.7%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY21 Q4 34.4%
FY22 Q4 27.2%
FY23 Q4 -35.7%
FY24 Q4 -153.1%
FY25 Q4 -46.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 4 6 5 5 24
Gross profit 1 2 2 2 1
EBITDA 0 0 0 −1 −11
Operating income 0 0 0 −1 −11
Net income −0 0 0 −1 10
Diluted EPS $0.00 $4.72 $13019.30 −$4408.76 $3.04
Growth (year on year)
Revenue — +44.3% −13.6% +5.8% +336.3%
EBITDA — +36.6% −85.3% — —
Operating income — +100.6% −89.4% — —
Net income — — −71.6% −503.0% —
Diluted EPS — — +>999% −133.9% —
Margins
Gross margin 24.9% 25.9% 32.7% 33.6% 4.0%
EBITDA margin 8.9% 8.4% 1.4% −21.0% −44.4%
Operating margin 4.8% 6.7% 0.8% −21.4% −45.2%
Net margin −0.0% 7.7% 2.5% −9.7% 41.7%
Free-cash-flow margin 34.4% 27.2% −35.7% −153.1% −46.7%
Cash flow
Cash from operations 1 2 −2 −8 −11
Capital spending 0 0 0 0 0
Free cash flow 1 2 −2 −8 −11
Stock-based pay 0 0 — −3 —
Free cash flow after stock pay 1 1 — −6 —
Balance sheet
Cash 0 0 0 0 1
Total debt 0 0 0 2 4
Net debt (negative = net cash) −0 −0 −0 2 4
Diluted shares — — — — 3m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · December 31, 2025
What it owns · $33m
Short-term assets $7mLonger-term assets $25m
What it owes, and who funded it · $33m
Short-term liabilities $2mLonger-term liabilities $4mShareholders' equity $27m
  • Short-term assets cover short-term liabilities $7m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $7m short-term assets against $4m of longer-dated liabilities.
  • More cash than debt $758,621 of cash against $4m of debt.
  • Debt below 40% of shareholders' equity Debt is 15% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$11m of operating cash flow against $4m of debt.
  • Operating profit covers interest at least five times over Operating income of −$11m against $616,423 of interest.

From Newgenivf Group Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2731009.2%
year over year

Competitors: side by side with peers

Closest by revenue in health care facilities
Last 12 months unless stated NIVF BMGL CCM SNDA NHC CON Median
Revenue, last 12 months $24m $13m $64m $526m $1.6bn $2.3bn $3.1bn
Revenue growth, last 12 months 336.3% 49.9% 20.1% 49.4% 6.9% 14.0% 14.0%
Revenue growth, 3-year average — — −11.2% 29.0% 12.8% — 8.1%
Revenue growth, latest quarter — — — 122.0% 8.8% 10.0% 8.6%
Gross margin 4.0% — 5.6% — — — 21.2%
Operating margin −45.2% — −56.8% −3.3% 9.3% 16.4% 9.0%
Operating margin, 3-year average — — −71.7% 0.0% 7.8% 15.9% 7.9%
Net margin 41.7% −4.5% −20.2% −23.3% 9.0% 8.7% 4.8%
Cash from operations / revenue −46.1% −3.9% −43.8% −3.0% 12.1% 14.7% 7.7%
Free-cash-flow margin −46.7% −5.4% −56.1% −10.0% 9.4% 11.7% 4.7%
Free-cash-flow margin, 3-year average — — −70.4% −6.9% 8.4% 10.2% 5.9%
Stock pay / revenue −50.9% 1.8% 0.0% 1.4% 0.3% 0.6% 0.6%
Change in share count >999% −91.6% 0.0% 57.5% 0.9% 1.6% 0.9%

Median of all 13 companies we cover in health care facilities. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care facilities companies
Measure Company Peer median Rank
Revenue growth Growth 336.3% 14.0% 1 of 13
Change in growth rate Growth +330.6pp -1.4pp 1 of 13
Operating margin Profitability -45.2% 9.0% 8 of 9
Net margin Profitability 41.7% 4.8% 1 of 13
Free-cash-flow margin Cash generation -46.7% 4.7% 12 of 13
Stock pay as % of revenue Cash generation -50.9% 0.6% 1 of 12
Long-term debt as % of assets Balance sheet 12.5% 37.7% 4 of 13
Change in share count Balance sheet 2731009.2% 0.9% 13 of 13

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$62
Institutions reporting
1
Positions opened / closed
1 / 0

Top buyers and sellers, Q2 2026: 1 institutions bought and 0 sold ; the biggest buyer was Sbi Securities Co., Ltd (+115 shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sbi Securities Co., Ltd. $62 0K 100.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Newgenivf Group Ltd's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $4.4M 8 trades by 2 insiders, last 12 months Insider sales History → $118,911 2 trades by 1 insider · 0% under pre-set plans
Net ▲ $4.2M net buying
Insider Date Trade Shares Price Value
Cheung Kong Yiu Director July 27, 2026 Buy 2,500,000 $1.00 $2.5M
Cheung Kong Yiu Director June 18, 2026 Buy 500,000 $1.33 $665,000
Hrt Financial Lp 10% owner June 4, 2026 Sell 64,945 $0.78 $50,657
Hrt Financial Lp 10% owner June 3, 2026 Buy 11,738 $0.88 $10,329
Cheung Kong Yiu Director June 2, 2026 Buy 500,000 $1.33 $665,000
Hrt Financial Lp 10% owner June 2, 2026 Buy 23,018 $0.94 $21,637
Cheung Kong Yiu Director May 28, 2026 Buy 222,223 $1.50 $333,334
Hrt Financial Lp 10% owner May 27, 2026 Sell 85,317 $0.80 $68,254
Hrt Financial Lp 10% owner May 26, 2026 Buy 27,993 $0.92 $25,754
Hrt Financial Lp 10% owner May 22, 2026 Buy 137,541 $0.99 $136,166

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Data status

When each part of this page on Newgenivf Group Ltd was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Newgenivf Group Ltd in brief

What does Newgenivf Group Ltd do?
Newgenivf Group Ltd is a US-listed company in the health care facilities industry. Its financial year ends in December.
What is Newgenivf Group Ltd's stock ticker?
Newgenivf Group Ltd trades under the ticker NIVF on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Newgenivf Group Ltd's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Newgenivf Group Ltd reported revenue of $23.7M, 336.3% higher than a year earlier, according to its SEC filings.
What is Newgenivf Group Ltd's free cash flow?
Newgenivf Group Ltd's free-cash-flow margin is -46.7% of revenue over the trailing twelve months, ranking 12 of the 13 health care facilities companies we cover.
What is Newgenivf Group Ltd's market cap?
On December 31, 2025, Newgenivf Group Ltd's market capitalisation was about $7.8B, with a price-to-earnings ratio of 784.5 and net debt of $3.6M. Market figures come from third-party market data and may be delayed.
How much debt does Newgenivf Group Ltd have?
Newgenivf Group Ltd's debt-to-equity ratio is 15.4%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Newgenivf Group Ltd's competitors?
In our Health Care Facilities peer group, the companies closest to Newgenivf Group Ltd are Basel Medical Group Ltd, Concord Medical Services Holdings Ltd, Sonida Senior Living, Inc., National Healthcare Corp and Concentra Group Holdings Parent, Inc. The side-by-side comparison below sets their revenue, margins and growth against Newgenivf Group Ltd's.
Are insiders buying or selling Newgenivf Group Ltd stock?
Over the last 12 months, Newgenivf Group Ltd's directors and officers reported 8 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.